Departments of Biotechnology and Medical Biotechnology

Departments of Biotechnology and Medical Biotechnology

Protein Enginnering For Life

News and Press Releases     History   ■   Directions  ■   Twitter

Aktive & Alumni - 3. Sept 2022 - 50 years of Biotechnology in Braunschweig
3. Sept 2022 - Members, Alumni and Friends of the Department of Biotechnology celebrate 50 years of Biotechnology in Braunschweig



April 23, 2021 - First COVID-19 patients treated with COR-101 drug developed in Braunschweig.

CORAT Therapeutics GmbH announced the start of a clinical trial with COR-101 for treatment of COVID-19 in hospitalized patients. The novel therapeutic antibody may complement currently approved antibody drugs, which are not indicated for moderate to severe COVID-19 cases due to side effects during advanced stages of the disease.

press release of CORAT Therapeutics

Website of CORAT Therapeutics

CORAT @ TU Braunschweig

Original publication

NEWS: Sept 6,2021 CORAT Therapeutics receives substantial funding from federal German ministries


Bispecific antibody

March 29, 2021 - Braunschweig anti-cancer antibody in clinical trials in the USA: New Drug Grips Tumor Cells With Two Arms.

The first patients with advanced tumors have been treated with the novel antibody-based drug M1231 in a clinical trial in the USA. It uses an invention of the Technical University of Braunschweig: The team of Professor Stefan Dübel, head of the Department of Biotechnology, discovered a human antibody that targets tumor cells and developed it over many years. This antibody is now part of a complex novel compound against difficult-to-treat cancers that is undergoing clinical testing by the pharmaceutical company Merck.

read more:  english - german


CORAT (Corona Antibody Team)

CORAT (within the Lab of Prof. Dr. Stefan Dübel, Prof. Dr. Michael Hust) developed an immunotherapy against COVID-19 using fully human monoclonal antibodies to prevent SARS-CoV2 infection.

CORAT Therapeutics GmbH is responsible for the clinical development

About us


The Department of Biotechnology is one of the divisions of the Institute for Biochemistry, Biotechnology and Bioinformatics. Founded in 1972, it was a key player in establishing biotechnology research in Braunschweig, and established the dedicated Biotechnology curriculum.

In 2002, Prof. Dr. Stefan Dübel joined the Department as director, adding the new research focus on Molecular Engineering, in particular Human Antibody Engineering and Phage Display. The Department quickly became the home to some of the world's largest and most successful academic human monoclonal antibody libraries, while the well established research focus on Biochemical Engineering, continued its succesful development until 2021, led by Prof. Dr. Siegmund Lang (ret.) and Prof. Dr. Udo Rau (ret.).

A major current focus was developed by Prof. Dr. Michael Hust on the fight against infectious diseases, leading to the installation of a dedicated Department of Medical Biotechnology in 2022.

Today, with fundamental and applied research topics spanning a very broad range including molecular and cell biology, infection biology, intrabodies, biomarker and drug discovery, vaccine development, synthetic biology and in vitro evolution,  TU Braunschweigs Biotechnology is well-endowed to embark into the challenges of cutting egde biotechnology research of the future, with a clear focus to increase the quality of life for everybody.

A long list of successful technology transfers includes the successful developmet of clinical stage anti-cancer and anti-virus antibodies, and novel approaches to avoid animal experiments for antibody generation. Several  spin-off biotech companies help to translate our discoveries into solutions for the benefit of all, and we will continue our efforts to pave new ways to develop designer medications for the 21st century.

Contact information

Department of Biotechnology
Institute for Biochemistry, Biotechnology and Bioinformatics
Technical University of Braunschweig

Management Assistants: Cornelia Oltmann, Silvia Seidel

Biocentre - Spielmannstr. 7
Room P101
D-38106 Braunschweig, Germany
Phone:    +49.531.391.5732
e-mail:    biotech(at)

Bitte beachten Sie: Sobald Sie die Kartenfunktion aktivieren, werden Daten an die OpenStreetMap Foundation übertragen. Weitere Informationen: OpenStreetMap Datenschutzerklärung (englisch).

By car: 

Please click on the city map logo above. GPS: 52.2743022, 10.531130

By train: 
For all railway connections, see Deutsche Bahn. Exit Braunschweig main station. Just in front, slightly left, are bus platforms. Take the bus line 419 (direction: Hauptbahnhof, leaves about every 10 min at workdays), exit at Gliesmaroder Straße (5th stop) or Bültenweg (6th stop) (klick map for larger version).
Bus connection details:

By air: 
Nearest airport with scheduled service is Hannover (HAJ). Best way of transfer to Braunschweig is to take an airport shuttle (45 min, needs reservation) or train (ca. 1,5 h, change of train at Hannover main station).
In some cases, particular from overseas, it may be faster to fly into Frankfurt (FRA) and take the comfortable ICE train to Braunschweig (3,5 hours); most ICE connections are via Frankfurt main railway station.
From Berlin's airports it takes about 2,5h by train or car - you may take a taxi to the Berlin main station and use the ICE train (1,3h) to Braunschweig.
For all railway connections, see Deutsche Bahn.

For visitors using their own aircraft, Braunschweig-Wolfsburg airport (IATA: BWE, ICAO: EDVE) is located 7km (15 min by Taxi) from the Institute. There are no scheduled public passenger services.
Position N52°19.16'  E10°33.53' in 297ft MSL, TORA2300m, ILS RWY 26, NDB/RNAV RWY 08/26 TWR 120,055 MHz, NDB BRU 427 kHz (all informations not for navigation)